What is the appropriate management of a patient with heart failure with reduced ejection fraction (HFrEF) who presents with hypotension?

Management of HFrEF with Hypotension

In HFrEF patients with hypotension, asymptomatic or mildly symptomatic low blood pressure should NOT prompt reduction or cessation of guideline-directed medical therapy (GDMT), as low BP does not indicate poor tolerance and these life-saving medications should be maintained or optimized using a structured sequencing approach. 1

Initial Assessment and Triage

Determine Severity and Symptoms

Critical hypotension (SBP <80 mmHg) or severe symptoms (significant orthostatic hypotension, profound fatigue, dizziness) require:

• Immediate referral to HF specialist or advanced HF program 1
• Assessment for shock or pre-shock with organ perfusion evaluation 1
• Consider hospitalization if signs of shock or severe congestion present 2

Asymptomatic or mildly symptomatic low BP (most common scenario):

• Proceed with structured GDMT optimization
• Patient education is critical—explain that transient dizziness is a side effect of life-prolonging drugs that reduce hospitalizations and improve quality of life 1

Identify the Etiology

If patient is stable on optimal GDMT with new-onset low BP:

• This is unlikely related to HF medications 1
• Evaluate for other causes:
  • Cardiovascular: valvular disease, myocardial ischemia
  • Non-cardiovascular: alpha-blockers for benign prostatic hyperplasia, antidepressants, other antihypertensives 1
• First step: Assess congestion status (clinical exam, biomarkers, lung/cardiac ultrasound)
  • If no congestion present, cautiously reduce diuretics 1
  • Stop unnecessary cardiac medications and non-HF antihypertensives 1

If GDMT was recently initiated or up-titrated:

• Hypotension is likely medication-related 1
• Proceed with medication sequencing strategy below

Medication Optimization Strategy for Low BP

For Treatment-Naïve Patients or Those Requiring Restart

Step 1: Initiate SGLT2 inhibitors and MRAs first

• These have the least effect on BP and may actually increase BP in some patients 1
• SGLT2i can be started even with eGFR >20 mL/min/1.73m² 1
• These provide rapid beneficial effects on outcomes

Step 2: Add beta-blocker OR ARNI/ACEI/ARB

• If heart rate >70 bpm: Start low-dose beta-blocker

  • Prefer selective β₁ receptor blockers (less BP-lowering than non-selective) 1
  • If beta-blocker not tolerated and patient in sinus rhythm, use ivabradine as alternative to facilitate later beta-blocker initiation 1
  • If atrial fibrillation with uncontrolled rate, consider digoxin 1

• For RAAS inhibition:

  • Start with very low-dose sacubitril/valsartan (25 mg twice daily) or low-dose (50 mg twice daily) 1
  • If sacubitril/valsartan not tolerated, use low-dose ACEI (or ARB if ACEI contraindicated) 1
  • Once adequate ACEI/ARB dose achieved, can transition to sacubitril/valsartan 1

Step 3: Titration Protocol

• Up-titrate one drug at a time with small increments 1
• Increase every 1-2 weeks 1
• Monitor closely with frequent follow-up
• Key principle: BP often improves as cardiac output increases, allowing easier up-titration 1

For Patients Already on GDMT

If symptomatic or persistent severe hypotension (SBP <90 mmHg):

1. Reduce or stop non-HF medications first 2

   • Antihypertensives without class I indication in HFrEF
   • Coordinate with other specialists for alternative medications with less BP-lowering effect 1

2. Adjust diuretics if no congestion 1, 2

   • Decrease loop diuretic dose cautiously
   • Avoid overdiuresis

3. If symptoms persist, consult HF specialist before modifying GDMT 2

   • Do NOT stop or reduce class I indicated medications without specialist input
   • When reduction necessary, start with the least tolerated medication 1

4. When BP improves, always rechallenge with previously reduced medications 1

   • Reinitiate based on best tolerated first
   • Strive to achieve optimal therapy

Common Pitfalls to Avoid

• Do not automatically reduce GDMT for asymptomatic low BP readings—this is the most common error and deprives patients of life-saving therapy 1
• Do not use BP thresholds from clinical trials as absolute contraindications—these were set to prevent dropouts and maintain statistical power, not based on safety concerns 1
• Do not overlook non-HF medications as culprits—always review entire medication list 1
• Do not forget patient education—reassurance about transient symptoms improves compliance 1

Special Considerations

Adjunctive therapies to facilitate GDMT optimization:

• Cardiac resynchronization therapy (CRT): Can improve BP and facilitate medication tolerance 1
• Transcatheter edge-to-edge repair (M-TEER): May increase forward stroke volume and BP, improving GDMT tolerability 3
• Midodrine: Off-label peripheral alpha-1 agonist can be considered in refractory symptomatic hypotension to allow GDMT optimization 4
• Ivabradine: Enables beta-blocker initiation/titration without additional BP lowering 1

The overarching principle: Maintain GDMT whenever possible, as these medications reduce mortality and hospitalizations even in the presence of low BP, provided patients have adequate organ perfusion and are not severely symptomatic. 1